Unichem Laboratories’ Ghaziabad facility has received an establishment inspection report (EIR) from the US health regulator.
The inspection was conducted by the United States Food and Drug Administration (USFDA) in April 2018, Unichem Laboratories said in a filing to the BSE today.
“Unichem’s formulation manufacturing facility at Ghaziabad has received an EIR from the USFDA indicating closure of inspection,” it added.
Shares of Unichem Laboratories were trading at Rs 234.60 per scrip on BSE, down 2.41 per cent from their previous close.
Published on June 5, 2018
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.